In this study we focused on primary non-goitrous congenital hypothyroidism (CHNG) likely to be caused by single gene defects. Therefore we executed our study in consanguineous families in whom recessive gene defects are the most likely cause for the development of the disease. In OMIM database four clinical entries with known genetic causes, CHNG 1, 2, 4, and 5, have been described to date (MIM numbers 275200, 218700, 275100, and 225250 respectively). The causative genes for these are respectively TSHR, PAX8, TSHB, and NKX2-5. There is one additional locus on The presence of parental consanguinity in individuals with a presumptive genetic condition is often an indicator of an autosomal recessive inheritance. In consanguineous families with autosomal recessively inherited disorders there is a high likelihood of mutation homozygosity (both parents having inherited the same mutation from a common ancestor) and so autozygosity mapping can provide a powerful strategy to map regions containing a disease gene. Conversely, candidate genes that are not contained within an autozygous segment are unlikely to cause the relevant disorder. We have ascertained a large cohort of consanguineous families (n=120) with non-goitrous congenital hypothyroidism (CHNG) and have undertaken genetic mapping and mutation analysis studies for four candidate genes (TSHR, PAX8, TSHB, and NKX2-5). We identified four novel and two previously reported TSHR mutations but most cases were not linked to any known CHNG genes. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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MATERIALS AND METHODS
Subjects
We collected blood samples from a total of 139 cases from 120 consanguineous families with primary non-syndromic CH without evidence of goitre or auto-immune thyroid disease. Families in which autosomal dominant inheritance was suspected, with at least one parent affected, were excluded from the study. Cases with clear evidence of central hypothyroidism were also excluded and almost all cases had elevated TSH levels at the time of diagnosis (range between 33 and 1578 mIU/L), levels for some cases not being available. Tissue scans showed a spectrum of thyroid morphologies ranging from agenesis to normal sized gland but none of the cases had enlarged gland at the time of diagnosis. 40 consanguineous families were recruited through the West Midlands Regional Clinical Genetics Service in Birmingham, UK. Most of these families were originated from the Mirpur region of Pakistan in whom CH occurs at an unusually high rate (1:770 live births). In addition 80 consanguineous Turkish families with CHNG were ascertained through four large clinical centres in Turkey where consanguinity rates are high. All families gave informed consent and the study was approved by local ethics committees. This study was conducted according to the principles stated in the Declaration of Helsinki. DNA was extracted by using standard methods and stored at -20°C until analysed.
Microsatellite marker analysis
Initially cases were genotyped by using microsatellite markers (short tandem repeatsSTRs) that closely flank the existing loci for CHNG (see Table 1 ). Even though we 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
RT-PCR
In one family a homozygous germline TSHR exon 2 deletion was suspected, and we proceeded to investigate the status of the TSHR transcript between exons 1 and 3. Thus we extracted RNA from all family members, synthesized their cDNA, and performed PCR and sequencing reactions with primers covering the region between the end of exon 1 and the beginning of exon 3. Total RNA was extracted from lymphocytes using the RNeasy Mini Kit (Qiagen), and then cDNA was synthesized using random primers and AMV reverse transcriptase using the Promega reverse transcription system A3500 according to manufacturers' instructions (Promega). The primers used for RT-PCR and sequencing reactions were: TSHR_1_FOR (5'-GAGAAATAGCCCCGAGTCCC-3') and TSHR_3_REV (5'-GAGTCACTTTACTCAAATTG -3'). 
Structural prediction model for missense mutations
To analyse the likely structural effects of the missense mutations identified in this work, we considered their evolutionary conservation, as illustrated by a multiple alignment of the top 50 Blast hits (performed using the Uniprot server). We also examined potential intermolecular interactions, to determine if they would be disrupted upon mutation.
TSHR is a G-coupled receptor with 764 amino acids, comprised of a large, extracellular leucine-rich repeat domain which binds the hormone, and a transmembrane domain with seven helices. Sanders et al. 3 solved the crystal structure of the extracellular domain, residues 1-213, in complex with a thyroid-stimulating antibody (PDB code 3G04). The transmembrane domain structure is not known, however the bovine rhodopsin structure (e.g. PDB code 1GZM 4 ) provides a suitable template for analysis or homology modelling (based on GRIS 5 and swissmodel.expasy.org 6 ). In addition, given the sequence similarity between TSHR and FSHR, the structure of the FSH/FSHR complex (PDB code 1XWD 7 )
suggests the most likely binding site of TSH with TSHR. Also, there is evidence that TSHR functions as a homodimer. To consider the structural effects on dimerisation, we analysed the dimer contacts of a published model of dimeric bovine rhodopsin (1N3M 8 ).
Finally, individual missense mutations may destabilise a protein domain, even to the extent of preventing folding. To consider this effect, we predicted quantitative stability changes (∆∆G D-N ) with the software tool SDM 9 (http://mordred.bioc.cam.ac.uk/~sdm/ sdm.php). 
RESULTS
Genotyping with 16 microsatellite markers associated with the TSHR, TSHB, PAX8 and NKX2-5 genes (see Table 1 Table 2 .
Direct sequencing of the TSHR gene was performed in 24 individuals from 16 kindreds in whom linkage to TSHR could not be excluded. Germline TSHR mutations were characterised in 6 kindreds (see Table 3 ). A homozygous G to A transition at codon 553 of the TSHR gene, causing substitution of an alanine residue by a threonine (A553T) was detected in two affected siblings from a family of Pakistani origin (B1). The parents and an unaffected sibling were heterozygous for this missense mutation confirming the segregation of the disease allele. Both affected children showed absent I 133 uptake in thyroid scintigraphy but had severely hypoplastic glands on ultrasonography at the time of diagnosis. Our studies showed that this mutation was significantly destabilising (∆∆G D-N -2.7) and that the Ala553 residue was conserved for 49 of the 50 sequences in our alignment.
A homozygous splice site mutation c.317+1G>A was identified in a Turkish family with two affected children (T1) and it segregated with disease status (both parents and an Three different homozygous missense mutations were detected in 3 Turkish families with a single affected individual (see Table 3 ). None of these 3 mutations were detected in 340
ethnically matched control chromosomes and each segregated with disease status. Family T2 with a homozygous p.Pro556Arg mutation presented when the proband was 3 months old. At the time of diagnosis a TSH level of >100 µU/mL (normal < 20 µU/mL) and a FT 4 level of 0,4 ng/dL (normal 0,8-1,9 ng/dL) were detected, and thyroid gland was not detected on scintigraphy or US scan. Even though treatment immediately started at the age of 3 months, the 11 year-old case now shows moderate mental retardation. At age 11 years a US scan showed an apparently absent right thyroid lobe and a very hypoplastic left lobe. We note that the proline556 residue is conserved in all of the 50 sequences in our alignment and located at the end of a transmembrane helix.
Two of the mutations characterised in this study (p.Pro162Ala and p.Arg531Trp) were associated with a milder phenotype. The case from family T3 had the missense mutation 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In family T5 exon 2 of the TSHR gene failed to amplify in the two affected siblings.
Analysis of the TSHR transcript by RT-PCR revealed two differently sized fragments in the parents. In cDNA derived from blood of both affected children only the smaller fragment (268 bp) was detected whereas both parents and an unaffected sibling also expressed a larger (340 bp) fragment (which corresponded to the expected size).
Sequencing confirmed that the 340 bp fragment contained exon 1, 2 and 3 sequence whereas the 268 bp fragment did not include exon 2 ( Figure 1 ). These findings were consistent with a homozygous exon 2 deletion in the two affected children.
Phenotypically, the older sibling had no activity in thyroid scintigraphy and a hypoplastic gland on US scan but hormone levels at diagnosis were not available. The younger sibling had a TSH level of 1578 mIU/L and a FT4 level of 0,16 ng/dL at the time of diagnosis, and his US scan detected a very hypoplastic thyroid tissue.
No mutations were detected in the TSHB, PAX8 and NKX2-5 in the patients in whom linkage to one or more of these genes could not be excluded. Figure   2 ). There are no known direct contacts, however it is in the local environment of the binding site so we predict it could slightly disrupt binding. The remaining missense mutations were found in three sites in the transmembrane domain. As the structure was not available, the stability predictions were made for the mutations at equivalent positions in bovine rhodopsin (PDB code 1GZM 4 ; see Table 4 and Figure 3 ; equivalent positions were found using an alignment made using Uniprot 10-11 and the alignments could be seen 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 is conserved at this site in all of the sequences in our alignment, and is found at the end of a helix, suggesting it is structurally required at this site. Individuals with autosomal recessively inherited disorders born into consanguineous families are most likely to be homozygous for a mutation inherited from a common parental ancestor. This observation is the basis for using an autozygosity mapping strategy to identify disease genes for recessively inherited disorders. Conversely the finding of heterozygosity at microsatellite markers flanking a disease gene makes it unlikely that the gene contains a mutation. In order to prioritise patients for gene sequencing we initially typed affected individuals for 16 microsatellite markers linked to the four disease genes. Whilst this might have excluded some patients who (despite being from consanguineous families) were compound heterozygotes or who harboured a homozygous mutation within a small region of autozygosity, such patients are likely to be infrequent. Mutation analysis demonstrated that 15% of the families with thyroid dysgenesis carried a TSHR mutation but no mutation was detected for the other three genes tested in our cohort. To our knowledge, we report the first large (exonic) deletion of TSHR. The exon 2 deletion is predicted to cause an in frame deletion (IFD) and skipping of exon 2 in the transcript. However this mutation would not have been detected if the probands had been heterozygous and our finding suggests that techniques that can 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The missense mutation p.Pro556Arg detected in family T2 was associated with a severe phenotype, suggesting a critical role for this residue in the structure of the molecule. Even though this change was not previously reported, another missense mutation at the same site (p.Pro556Leu) was characterised in severely hypothyroidic hyt/hyt mice and 18 . In vitro studies also revealed that p.Pro556Leu eliminated G proteincoupled cAMP production and cAMP-responsive reporter gene expression. Overall these data support the association of this mutation with the severe phenotype observed in our patient.
The missense mutation p.Pro162Ala associated with a mild phenotype in family T3
was previously described as a loss-of-function mutation and heterozygous carriers of this mutation had mild resistance to TSH manifesting as euthyroidism with slight hyperthyrotropinemia [19] [20] [21] . There have been only a few previous reports of homozygous individuals for this mutation and all four cases coming from three different consanguineous families had moderately elevated TSH levels (< 100 µU/mL) with normal thyroid radioiodine scan and FT 4 levels at normal range [22] [23] [24] . Similar phenotypic features of our case provide further evidence for the association of this mutation with a moderate TSH resistance. The other mild missense mutation detected in family T4, p.Arg531Trp, is the first naturally occurring homozygous mutation reported to date at this
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